Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous brincidofovir multiple ascending dose study in adult allogeneic hematopoietic cell transplant recipients with adenovirus viremia
2017-003984-37Phase 2Terminated
- Sponsor
- Chimerix Inc.
- Start
- Jun 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brincidofovir in adenoviral infection (2 arms), sponsored by Chimerix Inc. Primary endpoint: Safety and pharmacokinetics of intravenous brincidofovir. Started Jun 2018; status: terminated.
02
Drugs
brincidofovir
03
Conditions
adenoviral infection
Beyond the preview
Go deeper on 2017-003984-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003984-37.